KPTI — August Could Change EverythingKaryopharm Therapeutics, Inc.BATS:KPTIfinancialflagshipKaryopharm Therapeutics (KPTI) is an interesting biotech penny stock to watch as it approaches a major catalyst. The company already generates revenue from XPOVIO, but the real opportunity is its myelofibrosis program. Karyopharm is currently on track to submit an sNDA for selinexor + ruxolitinib under the FDA's Accelerated Approval pathway, with the potential to become the first approved combination therapy for myelofibrosis. The bullish case is therefore pretty straightforward: successful regulatory progress could significantly expand the company's addressable market and potentially trigger a major repricing. However, there is a major risk hanging over it. KPTI remains loss-making, with liquidity expected to fund operations only into September. The company also has a $15.8M loan payment due in September and is actively evaluating financing opportunities and strategic alternatives. Key dates to watch: Karyopharm plans to submit its myelofibrosis sNDA in August 2026, with the company also requesting Priority Review. Meanwhile, September 10 is another critical date, with a $15.8M loan payment due. Management is currently evaluating financing options and strategic alternatives as liquidity remains a major concern. From a technical perspective, this creates an interesting catalyst-driven setup. I'm watching for a breakout and a clear market structure shift before considering any bullish continuation. If the pattern unfolds before those 2 key dates it would give me a bit more confidence to trust a potential long. High fundamental risk, but potentially significant upside if the catalyst plays out.